Identification of the LINC00162/hsa-mir-383/CBX5 Axis as a novel prognostic biomarker associated with hemostasis in gastric cancer

Background: Gastric cancer is a significant global cause of cancer-related mortality, which requires the development of new biomarkers to enhance diagnosis and prognosis. Although long non-coding RNAs (lncRNAs) have become critical regulators in cancer biology, their significance in gastric cancer remains incompletely understood. Objective: The purpose of this study is to assess the potential of the LINC00162/hsa-mir-383/CBX5 axis as a prognostic biomarker associated with hemostasis by examining its expression and functional significance in gastric cancer. Methods: To identify differentially expressed lncRNAs, we conducted comprehensive in-silico analyses using TCGA-STAD datasets. Subsequently, we conducted experimental validation through qPCR in gastric cancer tissue samples. The LncACT and miRmap databases were employed to investigate the interactions between LINC00162, hsa-mir-383, and CBX5. In order to clarify the molecular pathways that were implicated, functional enrichment analysis was implemented. Results: In gastric cancer tissues, LINC00162 (PICSAR) was substantially overexpressed in comparison to normal samples, which was associated with adverse clinical outcomes. According to the lncRNA-microRNA interaction analysis, LINC00162 functions as a molecular reservoir for hsa-mir-383, a microRNA that is downregulated in gastric cancer. An upregulation of CBX5, a target gene that is implicated in the progression of cancer, is associated with this downregulation. Functional enrichment analysis indicates that this axis is involved in critical oncogenic pathways. Conclusion: The LINC00162/hsa-mir-383/CBX5 axis is a novel prognostic biomarker in gastric cancer that has substantial implications for the hemostasis process. These discoveries emphasize the critical role of lncRNAs in the pathogenesis of gastric cancer, opening up new opportunities for the development of diagnostic and therapeutic strategies. Additional research is necessary to investigate the clinical implications of targeting this axis in the treatment of gastric cancer.